In short, Mr. Guy Quigley is willing to subject your Company to this possible material adverse effect and to jeopardize the Company's product development and future operations, all in the name of avoiding a loss of control.
Quigley has loosely alluded to discovery responses made by Mr. Ted Karkus in recent litigation that Quigley began against him and other members of the his group (but, notably, that Quigley has since voluntarily abandoned). The Company's discovery was focused on officers and directors of The Quigley Corporation. Dr. Rosenbloom is neither an officer nor director of the Quigley Corporation and instead is on the staff of a wholly-owned subsidiary. Whatever else may be made of the record of the now-dismissed action, there is no proper basis for any claim of impropriety.
Unfortunately, the entire affair reveals the lengths that entrenched management will go, and the injury they are willing to inflict on both a key staff member of the Pharma subsidiary and the Company's overall interests, in order to stay in office.
The Karkus group respectively urges the shareholders to replace the Board of Directors on May 20, 2009, and elect directors that will put the interests of the Company and its shareholders first.
Only your last vote counts. Simply find the control # on our lightly shaded Blue Voting Instruction Form. This is the voting form that has the Ted Karkus list of Shareholder Nominees on it. Then call (800) 454-8683 or go to
|SOURCE Ted Karkus|
Copyright©2009 PR Newswire.
All rights reserved